Ruth Rabinowitz

Title: Ruth Rabinowitz: Innovator in Cannabinoid Therapeutics

Introduction

Ruth Rabinowitz is a prominent inventor based in Jerusalem, Israel. She has made significant contributions to the field of cannabinoid research, particularly in the development of therapeutic compounds. Her work focuses on the medical applications of cannabinoic quinones, which have the potential to treat various disorders.

Latest Patents

Rabinowitz holds a patent for "Compositions including quinonoid derivatives of cannabinoids for therapeutic use." This invention relates to cannabinoic quinone compounds, specifically five compounds designated as HU-331, HU-336, HU-345, HU-395, and HU-396. These compounds are described as active agents in pharmaceutical compositions aimed at treating inflammatory, infectious, auto-immune, and hyperproliferative disorders. Notably, these compounds may serve as anti-tumor agents or for cancer treatment. Among them, HU-345, HU-395, and HU-396 are recognized as novel cannabinoic quinones.

Career Highlights

Ruth Rabinowitz is affiliated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Her work has garnered attention for its innovative approach to cannabinoid therapeutics. With a focus on the medical use of cannabinoic quinones, she has positioned herself as a key figure in this emerging field.

Collaborations

Rabinowitz has collaborated with notable researchers, including Raphael Mechoulam and Natalya M Kogan. These partnerships have contributed to the advancement of cannabinoid research and the exploration of its therapeutic potential.

Conclusion

Ruth Rabinowitz's contributions to cannabinoid therapeutics highlight her role as an innovator in the field. Her patented work on cannabinoic quinones opens new avenues for the treatment of various medical conditions.